Literature DB >> 20733039

Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.

Claire M Martel1, Josie E Parker, Oliver Bader, Michael Weig, Uwe Gross, Andrew G S Warrilow, Nicola Rolley, Diane E Kelly, Steven L Kelly.   

Abstract

Sterol analysis identified four Candida albicans erg3 mutants in which ergosta 7,22-dienol, indicative of perturbations in sterol Δ(5,6)-desaturase (Erg3p) activity, comprised >5% of the total sterol fraction. The erg3 mutants (CA12, CA488, CA490, and CA1008) were all resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole under standard CLSI assay conditions (MIC values, ≥256, 16, 16, 8, and 1 μg ml⁻¹, respectively). Importantly, CA12 and CA1008 retained an azole-resistant phenotype even when assayed in the presence of FK506, a multidrug efflux inhibitor. Conversely, CA488, CA490, and three comparator isolates (CA6, CA14, and CA177, in which ergosterol comprised >80% of the total sterol fraction and ergosta 7,22-dienol was undetectable) all displayed azole-sensitive phenotypes under efflux-inhibited assay conditions. Owing to their ergosterol content, CA6, CA14, and CA177 were highly sensitive to amphotericin B (MIC values, <0.25 μg ml⁻¹); CA1008, in which ergosterol comprised <2% of the total sterol fraction, was less sensitive (MIC, 1 μg ml⁻¹). CA1008 harbored multiple amino acid substitutions in Erg3p but only a single conserved polymorphism (E266D) in sterol 14α-demethylase (Erg11p). CA12 harbored one substitution (W332R) in Erg3p and no residue changes in Erg11p. CA488 and CA490 were found to harbor multiple residue changes in both Erg3p and Erg11p. The results suggest that missense mutations in ERG3 might arise in C. albicans more frequently than currently supposed and that the clinical significance of erg3 mutants, including those in which additional mechanisms also contribute to resistance, should not be discounted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733039      PMCID: PMC2976150          DOI: 10.1128/AAC.00348-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Multiple resistance mechanisms to azole antifungals in yeast clinical isolates.

Authors:  D Sanglard; F Ischer; D Calabrese; M Micheli; J Bille
Journal:  Drug Resist Updat       Date:  1998       Impact factor: 18.500

2.  [Analysis of ERG11 gene mutation in Candida albicans].

Authors:  Ying-bin Wang; Hong Wang; Hui-yu Guo; Yong-zhong Zhao; Shen-qiu Luo
Journal:  Di Yi Jun Yi Da Xue Xue Bao       Date:  2005-11

3.  Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae.

Authors:  P F Watson; M E Rose; S L Kelly
Journal:  J Med Vet Mycol       Date:  1988-06

4.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

5.  Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome.

Authors:  Benjamin J Park; Beth A Arthington-Skaggs; Rana A Hajjeh; Naureen Iqbal; Meral A Ciblak; Wendy Lee-Yang; Mario D Hairston; Maureen Phelan; Brian D Plikaytis; Andre N Sofair; Lee H Harrison; Scott K Fridkin; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection.

Authors:  Stephen P Saville; Anna L Lazzell; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Eukaryot Cell       Date:  2003-10

8.  Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.

Authors:  Yonghao Xu; Lamei Chen; Chunyang Li
Journal:  J Antimicrob Chemother       Date:  2008-01-24       Impact factor: 5.790

9.  Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam.

Authors:  P E Boscott; G H Grant
Journal:  J Mol Graph       Date:  1994-09

10.  Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; D E Kelly
Journal:  Biochem Biophys Res Commun       Date:  1995-02-27       Impact factor: 3.575

View more
  72 in total

1.  S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole.

Authors:  Andrew G S Warrilow; Jonathan G L Mullins; Claire M Hull; Josie E Parker; David C Lamb; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

2.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Authors:  Erin M Vasicek; Elizabeth L Berkow; Stephanie A Flowers; Katherine S Barker; P David Rogers
Journal:  Eukaryot Cell       Date:  2014-03-21

4.  Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.

Authors:  Sabine Ottilie; Gregory M Goldgof; Claudia Magalhaes Calvet; Gareth K Jennings; Greg LaMonte; Jake Schenken; Edgar Vigil; Prianka Kumar; Laura-Isobel McCall; Eduardo Soares Constantino Lopes; Felicia Gunawan; Jennifer Yang; Yo Suzuki; Jair L Siqueira-Neto; James H McKerrow; Rommie E Amaro; Larissa M Podust; Jacob D Durrant; Elizabeth A Winzeler
Journal:  ACS Chem Biol       Date:  2016-12-23       Impact factor: 5.100

5.  Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and CDR1 Expression in Candida albicans.

Authors:  Andrew T Nishimoto; Qing Zhang; Brandon Hazlett; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 6.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

Review 7.  The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.

Authors:  Joachim Morschhäuser
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

8.  Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in Candida auris.

Authors:  Jian Bing; Tianren Hu; Qiushi Zheng; José F Muñoz; Christina A Cuomo; Guanghua Huang
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

9.  Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.

Authors:  Claire M Hull; Oliver Bader; Josie E Parker; Michael Weig; Uwe Gross; Andrew G S Warrilow; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

10.  Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Andrew P Davis; Paul R Rhomberg; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.